Detalles de la búsqueda
1.
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).
Ann Oncol
; 30(4): 612-620, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30657848
Resultados
1 -
1
de 1
1
Próxima >
>>